+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Retinoic Acid Receptor Gamma - Drugs In Development, 2021

  • PDF Icon

    Report

  • 88 Pages
  • August 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5438157
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 18 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 3, 7 and 2 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders, Immunology, Infectious Disease and Metabolic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Hand Dermatitis, Head And Neck Cancer, Inflammatory Bowel Disease, Kaposi Sarcoma, Keratoconjunctivitis Sicca (Dry Eye), Mantle Cell Lymphoma, Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

The latest report Retinoic Acid Receptor Gamma - Drugs In Development, 2021, outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most aniestractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionRetinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
  • ABIONYX Pharma SA
  • Advent Therapeutics Inc
  • Avecho Biotechnology Ltd
  • Bausch Health Companies Inc
  • Boehringer Ingelheim International GmbH
  • Galderma SA
  • Galephar Pharmaceutical Research Inc
  • Ipsen SA
  • Lee's Pharmaceutical Holdings Ltd
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Promius Pharma LLC
  • Sveikatal Inc
  • TherapyX Inc

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
  • Adapalene + benzoyl peroxide + clindamycin phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Adapalene + clindamycin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Benzoyl peroxide + tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPX-6001 + tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Alitretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Alitretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bexarotene + CD-1530 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Palovarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize RARG for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tazarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tazarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Trifarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued ProductsRetinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
Featured News & Press Releases
  • Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
  • May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)
  • Apr 22, 2021: Ortho Dermatologics announces statistically significant topline results from second pivotal phase 3 clinical trial evaluating IDP-126 gel in acne vulgaris
  • Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
  • Feb 24, 2021: Galderma and Aklief (trifarotene) cream, 0.005% unveil me being me campaign to inspire young people with acne to live life to the fullest
  • Feb 09, 2021: Lee’s Pharmaceutical Holdings: Update on an investigational dermatology product
  • Nov 16, 2020: Trifarotene in moderate acne: no study data for the assessment of the added benefit
  • Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results
  • Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting
  • Jul 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
  • Jun 23, 2020: Ortho Dermatologics launches ARAZLO (tazarotene) lotion, 0.045%, in the United States
  • Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
  • Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
  • Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
  • Jan 08, 2020: Certara partners with Galderma in advancing modeling and simulation technology to attain FDA approval of AKLIEF topical Acne cream

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by ABIONYX Pharma SA, 2021
  • Pipeline by Advent Therapeutics Inc, 2021
  • Pipeline by Avecho Biotechnology Ltd, 2021
  • Pipeline by Bausch Health Companies Inc, 2021
  • Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Pipeline by Galderma SA, 2021
  • Pipeline by Galephar Pharmaceutical Research Inc, 2021
  • Pipeline by Ipsen SA, 2021
  • Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021
  • Pipeline by Orphanix GmbH, 2021
  • Pipeline by Ortho Dermatologics Inc, 2021
  • Pipeline by Promius Pharma LLC, 2021
  • Pipeline by Sveikatal Inc, 2021
  • Pipeline by TherapyX Inc, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ABIONYX Pharma SA
  • Advent Therapeutics Inc
  • Avecho Biotechnology Ltd
  • Bausch Health Companies Inc
  • Boehringer Ingelheim International GmbH
  • Galderma SA
  • Galephar Pharmaceutical Research Inc
  • Ipsen SA
  • Lee's Pharmaceutical Holdings Ltd
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Promius Pharma LLC
  • Sveikatal Inc
  • TherapyX Inc